Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELICAN: RFA + Chemotherapy in LAPC
NCT03690323Unknown
- Sponsor
- University of Amsterdam
- Start
- Apr 2015
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by University of Amsterdam. Primary endpoint: Overall Survival at 1.5 years. Status: unknown.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03690323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690323.